HIV pre-exposure prophylaxis for women

Area of Science:

• Public Health
• Infectious Diseases
• Women's Health

Background:

• Women and girls represent a significant proportion of global HIV infections.
• HIV pre-exposure prophylaxis (PrEP) is a crucial, yet underutilized, prevention strategy for women.
• Addressing challenges in PrEP delivery for women is essential for public health.

Purpose of the Study:

• To highlight the importance of optimizing HIV prevention options for women.
• To discuss the efficacy and underutilization of HIV pre-exposure prophylaxis (PrEP) in women.
• To identify challenges and opportunities for improving PrEP uptake among women.

Main Methods:

• Review of clinical trial data on the efficacy of daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for women.
• Analysis of factors contributing to the suboptimal use of PrEP in women.
• Exploration of potential strategies to enhance PrEP delivery and integration with reproductive healthcare.

Main Results:

• Daily oral TDF/FTC demonstrates efficacy in reducing HIV acquisition among women when used consistently.
• Limited HIV risk perception and insufficient PrEP awareness among women and healthcare providers are key barriers.
• Current PrEP utilization among women remains suboptimal despite proven efficacy.

Conclusions:

• Optimizing PrEP for women requires addressing awareness and risk perception issues.
• Integrating PrEP services with existing reproductive healthcare can improve access and utilization.
• Further research into novel drugs and delivery systems is needed to enhance female-controlled HIV prevention.